Deciphering the Impact of RAC1‐SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models
Advanced Science · 2026-05 · 13 (25)
DOI: 10.1002/advs.202524001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 26.02.2026. Verfasst von Shohei Kuraoka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: rac1 GTP-Binding Protein, Polycystic Kidney, Autosomal Recessive, Microfilament Proteins, Neuropeptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Autosomal recessive polycystic kidney disease (ARPKD) leads to severe renal cysts and progressive kidney dysfunction, with no approved treatments. The absence of such cystic phenotypes in Pkhd1 − / − mice underscores the need for novel models that better recapitulate the human disease. We developed kidney organoid‐on‐chip models that mimic patients’ distal‐nephron cysts, identifying RAC1/c‐FOS as potential therapeutic targets. However, critical questions remain regarding RAC1 activation during cyst formation, cyst origins, and underlying molecular mechanisms. Using a multifaceted approach, organoid‐on‐chip models, transgenic mice, and patient kidney samples, we identified reduced levels of SPTAN1, a cytoskeletal spectrin protein, as a key regulator of RAC1 activation and cystic pathology. SPTAN1‐mutant kidney organoids and mice exhibited distal‐nephron cysts, and elevated RAC1/c‐FOS expression, consistent with ARPKD patients. Transcriptomics and live imaging revealed altered calcium signaling and increased intracellular calcium. Single‐cell RNA‐seq identified SLC8A1, a sodium/calcium exchanger, as a marker distinguishing distal/connecting tubules from collecting ducts in human kidneys, predominantly expressed in cystic epithelia in organoids and human ARPKD kidneys. Restoring SPTAN1 in PKHD1 − / − organoids via CRISPR activation alleviated cystic phenotypes, normalized intracellular calcium, and reduced RAC1/c‐FOS expression. These findings position SPTAN1 as a central player in ARPKD pathogenesis and highlight epigenome editing as a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
ORCID-Profile: Ryuji Morizane
Förderung
- NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Kuraoka, S., Higashi, Y., Saito, S., Pourgonabadi, S., Honjoh, H., Ishigaki, S., Harris, P. C., Satlin, L. M., Yamashita, M., & Morizane, R. (2026). Deciphering the Impact of RAC1‐SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models. Advanced Science, 13(25). https://doi.org/10.1002/advs.202524001
Vancouver
Kuraoka S, Higashi Y, Saito S, Pourgonabadi S, Honjoh H, Ishigaki S, et al. Deciphering the Impact of RAC1‐SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models. Advanced Science. 2026;13(25). doi:10.1002/advs.202524001
BibTeX
@article{Kuraoka2026,
author = {Kuraoka, Shohei and Higashi, Yuhei and Saito, Suguru and Pourgonabadi, Solmaz and Honjoh, Honami and Ishigaki, Sho and Harris, Peter C and Satlin, Lisa M and Yamashita, Michifumi and Morizane, Ryuji},
title = {Deciphering the Impact of RAC1‐SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {25},
doi = {10.1002/advs.202524001}
}
EUVIMED